Cryoport, Inc.

CYRX Biotech & pharma

Develops temperature-controlled supply chains for cell and gene therapies.

Jun 2026Revenue $186M/yrExpenses $226M/yr
No trendCash runway over 10 years from Jun 2026
Figures by year

When will Cryoport be profitable?

Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $186M and expenses $226M.

Fiscal year toRevenueExpensesOperating profit
Dec 2025$176M$213M−$36.8M
Dec 2024$157M$278M−$122M
Dec 2023$169M$269M−$101M
Dec 2022$237M$269M−$31.9M
Dec 2021$223M$240M−$17.8M
Dec 2020$78.7M$109M−$30.0M
Dec 2019$33.9M$51.6M−$17.7M
Dec 2018$19.6M$28.3M−$8.64M
Dec 2017$12.0M$19.8M−$7.89M
Dec 2016$7.68M$16.4M−$8.77M